The flavones apigenin and luteolin induce FOXO1 translocation but inhibit gluconeogenic and lipogenic gene expression in human cells

PLoS ONE

Volumn 9, Issue 8, 2014, Pages

  Bumke Vogt, Christiane ^a,b   Osterhoff, Martin A ^a,b   Borchert, Andrea ^a   Guzman Perez, Valentina ^a,c   Sarem, Zeinab ^a   Birkenfeld, Andreas L ^b   Bähr, Volker ^b   Pfeiffer, Andreas F H ^a,b  

^a GERMAN INSTITUTE OF HUMAN NUTRITION   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c PONTIFICIA UNIVERSIDAD JAVERIANA   (Colombia)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYL COENZYME A CARBOXYLASE; ACETYLCYSTEINE; APIGENIN; FATTY ACID SYNTHASE; GLUCOSE 6 PHOSPHATASE; LUTEOLIN; MESSENGER RNA; PHOSPHOENOLPYRUVATE CARBOXYKINASE (GTP); PROTEIN KINASE B; S6 KINASE; SIRTUIN 1; SMALL INTERFERING RNA; SOMATOMEDIN C RECEPTOR; TRANSCRIPTION FACTOR FKHR; TRANSCRIPTION FACTOR FKHRL1; TRANSCRIPTION FACTOR NRF2; ACACA PROTEIN, HUMAN; AKT1S1 PROTEIN, HUMAN; ANTIDIABETIC AGENT; FASN PROTEIN, HUMAN; FORKHEAD TRANSCRIPTION FACTOR; FOXO1 PROTEIN, HUMAN; INSULIN; NFE2L2 PROTEIN, HUMAN; PHOSPHOENOLPYRUVATE CARBOXYKINASE (ATP); SIGNAL TRANSDUCING ADAPTOR PROTEIN; SIRT1 PROTEIN, HUMAN;

ARTICLE; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; ENZYME PHOSPHORYLATION; GENE CONTROL; GENE EXPRESSION; GENETIC TRANSFECTION; HEPG2 CELL LINE; HUMAN; HUMAN CELL; OXIDATIVE STRESS; REAL TIME POLYMERASE CHAIN REACTION; RNA ISOLATION; SIGNAL TRANSDUCTION; U2OS CELL LINE; CYTOLOGY; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; HEK293 CELL LINE; METABOLISM; OSTEOBLAST; TUMOR CELL LINE;

ACETYL-COA CARBOXYLASE; ADAPTOR PROTEINS, SIGNAL TRANSDUCING; APIGENIN; CELL LINE, TUMOR; FATTY ACID SYNTHASE, TYPE I; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION REGULATION; GLUCOSE-6-PHOSPHATASE; HEK293 CELLS; HEP G2 CELLS; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; LUTEOLIN; NF-E2-RELATED FACTOR 2; OSTEOBLASTS; PHOSPHOENOLPYRUVATE CARBOXYKINASE (ATP); PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, IGF TYPE 1; SIGNAL TRANSDUCTION; SIRTUIN 1;

EID: 84924634426     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0104321     Document Type: Article

References (30)

1. Paulweber B, Valensi P, Lindstrom J, Lalic NM, Greaves CJ, et al. (2010) A European Evidence-Based Guideline for the Prevention of Type 2 Diabetes. Hormone and Metabolic Research 42: S3-S36.
2. Popkin BM, Adair LS, Ng SW (2011) Global nutrition transition and the pandemic of obesity in developing countries. Nutrition Reviews 70: 3-21.
3. Eckel RH, Grundy SM, Zimmet PZ (2005) The metabolic syndrome. Lancet 365: 1415-1428. (Pubitemid 40523737)
4. Crandall JP, Knowler WC, Kahn SE, Marrero D, Florez JC, et al. (2008) The prevention of type 2 diabetes. Nature Clinical Practice Endocrinology & Metabolism 4: 382-393. (Pubitemid 351881862)
5. Weickert MO, Roden M, Isken F, Hoffmann D, Nowotny P, et al. (2011) Effects of supplemented isoenergetic diets differing in cereal fiber and protein content on insulin sensitivity in overweight humans. American Journal of Clinical Nutrition 94: 459-471.
6. Cooper AJ, Sharp SJ, Lentjes MAH, Luben RN, Khaw KT, et al. (2012) A Prospective Study of the Association Between Quantity and Variety of Fruit and Vegetable Intake and Incident Type 2 Diabetes. Diabetes Care 35: 1293-1300.
7. Brasnyo P, Molnar GA, Mohas M, Marko L, Laczy B, et al. (2011) Resveratrol improves insulin sensitivity, reduces oxidative stress and activates the Akt pathway in type 2 diabetic patients. British Journal of Nutrition 106: 383-389.
8. Crandall JP, Oram V, Rescu GT, Reid M, Kishore P, et al. (2012) Pilot Study of Resveratrol in Older Adults With Impaired Glucose Tolerance. Journals of Gerontology Series a-Biological Sciences and Medical Sciences 67: 1307-1312.
9. Timmers S, Konings E, Bilet L, Houtkooper RH, van de Weijer T, et al. (2011) Calorie Restriction-like Effects of 30 Days of Resveratrol Supplementation on Energy Metabolism and Metabolic Profile in Obese Humans. Cell Metabolism 14: 612-622.
10. Poulsen MM, Vestergaard PF, Clasen BF, Radko Y, Christensen LP, et al. (2013) High-Dose Resveratrol Supplementation in Obese Men An Investigator-Initiated, Randomized, Placebo-Controlled Clinical Trial of Substrate Metabolism, Insulin Sensitivity, and Body Composition. Diabetes 62: 1186-1195.
11. Salas-Salvado J, Bullo M, Estruch R, Ros E, Covas MI, et al. (2014) Prevention of diabetes with Mediterranean diets: a subgroup analysis of a randomized trial. Ann Intern Med 160: 1-10.
12. Barthel A, Schmoll D, Unterman TG (2005) FoxO proteins in insulin action and metabolism. Trends in Endocrinology and Metabolism 16: 183-189. (Pubitemid 40603098)
13. Daitoku H, Hatta M, Matsuzaki H, Aratani S, Ohshima T, et al. (2004) Silent information regulator 2 potentiates Foxo1-mediated transcription through its deacetylase activity. Proceedings of the National Academy of Sciences of the United States of America 101: 10042-10047. (Pubitemid 38891191)
14. Daitoku H, Sakamaki J, Fukamizu A (2011) Regulation of FoxO transcription factors by acetylation and protein-protein interactions. Biochimica Et Biophysica Acta-Molecular Cell Research 1813: 1954-1960.
15. Motta MC, Divecha N, Lemieux M, Kamel C, Chen D, et al. (2004) Mammalian SIRT1 represses forkhead transcription factors. Cell 116: 551-563. (Pubitemid 38264432)
16. van der Horst A, de Vries-Smits AMM, Brenkman AB, van Triest MH, van den Broek N, et al. (2006) FOXO4 transcriptional activity is regulated by monoubiquitination and USP7/HAUSP. Nature Cell Biology 8: 1064-U1040.
17. van der Horst A, Burgering BMT (2007) Stressing the role of FoxO proteins in lifespan and disease. Nature Reviews Molecular Cell Biology 8: 440-450.
18. Eijkelenboom A, Burgering BMT (2013) FOXOs: signalling integrators for homeostasis maintenance. Nature Reviews Molecular Cell Biology 14: 83-97.
19. Lopez-Lazaro M (2009) Distribution and Biological Activities of the Flavonoid Luteolin. Mini-Reviews in Medicinal Chemistry 9: 31-59.
20. Marniemi J, Alanen E, Impivaara O, Seppanen R, Hakala P, et al. (2005) Dietary and serum vitamins and minerals as predictors of myocardial infarction and stroke in elderly subjects. Nutrition Metabolism and Cardiovascular Diseases 15: 188-197. (Pubitemid 40934163)
21. Jang S, Kelley KW, Johnson RW (2008) Luteolin reduces IL-6 production in microglia by inhibiting JNK phosphorylation and activation of AP-1. Proceedings of the National Academy of Sciences of the United States of America 105: 7534-7539. (Pubitemid 351830053)
22. Lien EJ, Ren SJ, Bui HYH, Wang RB (1999) Quantitative structure-activity relationship analysis of phenolic antioxidants. Free Radical Biology and Medicine 26: 285-294. (Pubitemid 29013458)
23. Shukla S, Gupta S (2010) Apigenin: A Promising Molecule for Cancer Prevention. Pharmaceutical Research 27: 962-978.
24. Zhang X, Gan L, Pan H, Guo S, He X, et al. (2002) Phosphorylation of serine 256 suppresses transactivation by FKHR (FOXO1) by multiple mechanisms. Direct and indirect effects on nuclear/cytoplasmic shuttling and DNA binding. J Biol Chem 277: 45276-45284. (Pubitemid 36159133)
25. Arafat AM, Weickert MO, Frystyk J, Spranger J, Schofl C, et al. (2009) The role of insulin-like growth factor (IGF) binding protein-2 in the insulin-mediated decrease in IGF-I bioactivity. J Clin Endocrinol Metab 94: 5093-5101.
26. Xiong S, Salazar G, Patrushev N, Alexander RW (2011) FoxO1 mediates an autofeedback loop regulating SIRT1 expression. J Biol Chem 286: 5289-5299.
27. Besse-Patin A, Estall JL (2014) An Intimate Relationship between ROS and Insulin Signalling: Implications for Antioxidant Treatment of Fatty Liver Disease. Int J Cell Biol 2014: 519153.
28. Ruela-de-Sousa RR, Fuhler GM, Blom N, Ferreira CV, Aoyama H, et al. (2010) Cytotoxicity of apigenin on leukemia cell lines: implications for prevention and therapy. Cell Death & Disease 1.
29. Park JM, Kim TH, Bae JS, Kim MY, Kim KS, et al. (2010) Role of resveratrol in FOXO1-mediated gluconeogenic gene expression in the liver. Biochem Biophys Res Commun 403: 329-334.
30. Okada K, Warabi E, Sugimoto H, Horie M, Gotoh N, et al. (2013) Deletion of Nrf2 leads to rapid progression of steatohepatitis in mice fed atherogenic plus high-fat diet. J Gastroenterol 48: 620-632.